Elsberg syndrome (ES) is a presumed infectious syndrome consisting of acute or subacute bilateral lumbosacral radiculitis, often accompanied by myelitis confined to the lower spinal cord, and is frequently a manifestation of reactivation, or occasionally, primary herpes simplex virus 2 (HSV2) infection.^[@R1]^ Clinicians often do not consider ES in the differential diagnosis of acute cauda equina syndrome (CES) and do not perform appropriate testing for HSV infection in a timely way to facilitate definitive diagnosis. However, especially when accompanied by clinical or radiologic findings of myelitis, ES is not a rare cause of CES. ES has been the subject of case reports and small series,^[@R2][@R3][@R7]^ the largest of which included 17 patients.^[@R8]^ A formal case definition that defines the minimum criteria to diagnose this syndrome and identifies exclusionary findings that suggest alternative diagnoses does not exist. Sarcoidosis, lymphoma, other neoplasms, and vascular disorders (dural arteriovenous fistula) may mimic ES and are in the differential diagnosis.

We conducted a retrospective review of lumbosacral myeloradiculitis evaluated at the Mayo Clinic to assess the frequency of ES, determined retrospectively as well as prospectively. Among cases who did not have other established diagnoses and who met certain minimum criteria, we reviewed Mayo clinical records to classify the level of diagnostic certainty using a scheme we derived based on a review of the medical literature ([table 1](#T1){ref-type="table"}). We identified clinical, demographic, and radiologic findings of ES, concentrating on distinction from other causes of lower thoracic/conus myelitis.

###### 

Elsberg syndrome according to diagnostic certainty
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METHODS {#s1}
=======

We performed a retrospective review of Mayo electronic medical records from 2000 to March 2016 interrogating for the term "Elsberg" in the history, examination, review of systems, impression, and final diagnosis and thereby identified only 4 patients. To find unrecognized cases, we searched again for a combination of key terms common to those of the 4 ES cases in patients evaluated in the neurology, urology, gynecology, or infectious disease departments who had both myelitis and radiculitis ([figure 1](#F1){ref-type="fig"}). After testing several possible combinations of terms, we selected patients identified by at least 1 of 4 searches of the medical records, components of which are highlighted in flow chart in [figure 1](#F1){ref-type="fig"}, and thereby identified 1,035 patients. We excluded patients with an *International Classification of Disease* (*ICD*) diagnosis of MS or neuromyelitis optica (NMO), reducing the cohort to 837 subjects. Exclusion of cases without terms referring to urinary retention or sacral sensory symptoms further reduced the cohort to 337 subjects. A review of individual clinical records identified 213 patients with other definitive alternative diagnoses ([table 2](#T2){ref-type="table"}). Subsequently, we conducted a detailed review of clinical records to confirm the presence of urinary retention or other sacral symptoms (saddle anesthesia, paresthesias, neuralgic pain, constipation, impotence, urinary incontinence, and fecal incontinence) yielding 49 patients who were strongly suspected to have ES ([figure 1](#F1){ref-type="fig"}). We abstracted their demographic characteristics, neurologic examination findings, CSF, viral, EMG, and MRI results from clinical records. The Mayo Clinic Institutional Review Board granted approval to review retrospectively obtained patient clinical information.

![Flow chart of patient selection\
Interrogation of the electronic database for specific key terms highlighted in the first box returned a list of 1,035 patients. We excluded patients with an *ICD* code identifying NMO and MS, yielding 837 patients. Further interrogation of the database for patients with the following key terms returned 337 patients: "urinary retention" OR "paresthesia" OR "neuralgic pain" OR "constipation" OR "impotence" OR "perineal" OR "retention" OR "anus" OR "anal" OR "saddle". After the review of individual clinical records of the remaining patients, we excluded 213 subjects who had likely or established alternative diagnoses, as listed in the figure, and only patients who were confirmed to have urinary retention and other sacral sensory symptoms were retained. Of the remaining 49 patients, 19 did not satisfy any of the levels of diagnostic certainty proposed in [table 1](#T1){ref-type="table"}. The remaining 30 were assigned a specific diagnostic category according to the level of suspicion for ES. ES = Elsberg syndrome; *ICD* = *International Classification of Disease*; NMO = neuromyelitis optica.](NEURIMMINFL2017012427FF1){#F1}

We defined diagnostic criteria for ES with 5 levels of diagnostic certainty based on the review of the medical literature: laboratory-supported definite, clinically definite, clinically probable, clinically possible, and excluded ([table 1](#T1){ref-type="table"}). Radiculitis, defined either clinically ([table 1](#T1){ref-type="table"}, A1) or by MRI and/or electrophysiologic evidence ([table 1](#T1){ref-type="table"}, A2), was required to establish a diagnosis of ES. A neurologist (B.G.W.) categorized each case according to these criteria and with special attention to potential alternative diagnoses. A neuroradiologist (T.K.) reviewed abnormal radiology to confirm and further characterize the abnormalities in each case and to consider whether there were unique or characteristic radiologic features of ES after the review of the entire cohort.

###### 

Alternative diagnoses established or likely (213 patients)
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We report the frequencies of key clinical and radiologic features and summarize distinctive radiologic features.

RESULTS {#s2}
=======

Forty-nine patients satisfied the inclusion and exclusion criteria. Clinical and MRI findings are summarized in [table 3](#T3){ref-type="table"} and the clinical course in [table 4](#T4){ref-type="table"}. Three patients met criteria for laboratory-supported definite, 9 for clinically definite, 10 for clinically probable, and 8 for clinically possible ES. Nineteen patients were excluded, 16 (84%) because of exclusionary criteria ([table 1](#T1){ref-type="table"}) and 3 (16%) because they failed to satisfy any of the established levels of diagnostic certainty ([table 1](#T1){ref-type="table"}), including 2 of the 4 diagnosed with ES at the time of their clinical evaluation but with insufficient information to confirm the diagnosis. Based on MRI and EMG, available in 29 and 21 cases respectively, 2 patients had only myelitis, 5 only radiculitis, and 16 both. Only 2 included patients had been diagnosed with ES at the time of their clinical evaluation.

###### 

Key clinical and radiologic features
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###### 

Summary of treatments and clinical course
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Of the 30 patients with a diagnosis of lab-supported, definite, probable, or possible ES, 24 (80%) were men and 6 women (20%) and their median age was 53 years. Five patients (17%) experienced prodromal symptoms, including fever, headache, photophobia, diarrhea, myalgia, and general malaise. Sacral herpes infection (zoster, n = 1; simplex, n = 1) immediately preceded clinical presentation in 2 patients and oral herpes simplex in 1 patient. Urinary retention was present in 23 (77%) patients and required indwelling catheterization in 21 (70%) patients. Saddle anesthesia (n = 15, 50%) and constipation (n = 13, 43%) were common. Fifteen (50%) patients had weakness of the lower limbs worse than 3/5 on the MRC scale in 7 patients (23%). Lower limb tendon reflexes were pathologically exaggerated in 10 patients (33%) and absent in 10 (33%); 4 (13%) had unequivocal and 6 (20%) patients had equivocal Babinski signs.

Eighteen patients (60%) were tested for viral infection, in particular for HSV (n = 16, 53%), varicella zoster virus (VZV) (n = 15, 50%), cytomegalovirus (n = 15, 50%), Epstein-Barr virus (n = 17, 57%), and HIV (n = 17, 57%). PCR confirmed viral infection in 3 patients (10%); in 2 patients, VZV was demonstrated in the CSF and, in 1 patient, HSV2 from a genital swab. Three patients were tested for Lyme disease, all with negative results. Radiculitis was confirmed in 21 patients (70%) by MRI with gadolinium (n = 17, 57%) or EMG (n = 12, 40%). MRI showed lumbar or lower thoracic cord T2-hyperintense signal abnormality in 18 patients (60%) and cord gadolinium enhancement in 13 patients (43%). Sixteen patients (53%) had MRI evidence of concomitant myelitis and radiculitis ([figure 2](#F2){ref-type="fig"}). Six patients (20%) had relatively minor MRI abnormalities within the spinal cord that extended rostral to T9--T10; in patients whose dominant cord lesion was caudal to T9, minor exceptions were allowed to the rule of excluding those with spinal cord abnormalities extending rostral to T9. Spinal cord lesions were multiple and discontinuous in 9 cases (30%) and were centrally or ventrally positioned within the cord. In 2 patients, the lesions were mildly expansile. In 3 cases (10%), the lesion was only present in the lower thoracic cord, not in the conus. Nerve root enhancement was always smooth rather than nodular, occasionally diffuse, and sometimes limited to ventral or dorsal roots. Thirteen patients (43%) had MRI evidence of nerve root thickening. Nerve root enhancement often occurred contemporaneously with spinal cord involvement; evaluation of MRI at multiple time points, when available, showed that in 3 cases (10%) root enhancement occurred at a later point of the illness as cord lesions were resolving.

![MRI evidence of myelitis and radiculitis in 6 patients\
Patient A presents with concomitant presence of multiple and discontinuous T2 hyperintense lesions (A.a) that enhance on T1-weighted images after gadolinium injection (A.b) concomitantly with nerve roots of the cauda equina (A.b and A.c). Nerve root enhancement is prominent in 2 other patients (B.a, B.b, C.a, and C.b), with greater nerve root thickening in the latter (C.c). Two other patients had multifocal, discontinuous, T2-hyperintense lesions (D.a and E.a) as well as enhancement (D.b and E.b) in both the conus and lower thoracic cord. Finally, cord T2-hyperintense abnormality (F.a) may precede the onset of nerve root enhancement (F.b) by 26 days.](NEURIMMINFL2017012427FF2){#F2}

The median CSF white blood cell count in the Elsberg group was 9; 15 (50%) patients had more than 5 leukocytes/μL; the average percentage of lymphocytes was 69%; 2 patients had an average 65% mononuclear predominance. CSF proteins were consistently elevated (mean 143 ± 131 mg/dL), whereas oligoclonal bands were rarely detected ([table 3](#T3){ref-type="table"}).

ES was considered in the differential diagnosis of 3 (10%) patients. Acyclovir was administered in 6 (20%) patients and corticosteroids in 15 (50%) patients, typically methylprednisolone 1 g per day over 3--5 days. Follow-up data were available for 13 (43%) patients ([table 4](#T4){ref-type="table"}). One patient (3%) died with encephalomyelitis and cardiac arrest; 3 patients (10%) had no neurologic recovery; 8 moderate recovery (27%); and 1 complete recovery (3%). Only 2 patients (7%) relapsed, one at 33 and the other at 82 months from onset.

DISCUSSION {#s3}
==========

ES is poorly defined and rarely reported, but it is probably frequently unrecognized. Based on the historical literature and our clinical experience, we formulated objective criteria for ES with 4 different levels of certainty ([table 1](#T1){ref-type="table"}). Radiculitis, manifest either clinically ([table 1](#T1){ref-type="table"}, A1), radiologically or electrophysiologically ([table 1](#T1){ref-type="table"}, A2) is required. A secure diagnosis is possible when evidence for infection by a causative virus is demonstrated and alternative causes excluded, but given the sensitivity of the serologic and virologic studies^[@R9]^ and frequent delay in obtaining appropriate samples, clinical and radiologic evidence may suggest ES regardless of the microbiologic information. For this reason, we established criteria for clinically definite, probable, and possible ES (see supportive feature in [table 1](#T1){ref-type="table"}, B1--B5). In addition, we identified red flags that are cautionary but not exclusionary as well as exclusionary criteria ([table 1](#T1){ref-type="table"}, C and D).

The onset of ES was consistently acute in our cohort; insidious onset and evolution suggest alternative explanations such as sarcoidosis or neoplasm. Suspected cauda equina involvement, which leads to urinary retention, is confirmed with MRI and/or EMG. Concomitant myelitis detected radiologically or clinically further supports the diagnosis. Myelitis, associated with many inflammatory CNS conditions such as MS, NMO, anti-MOG antibody myelitis, sarcoidosis, and others, is not usually associated with radiculitis, whereas radiculitis is a required feature for the diagnosis of ES.

We did not identify pathognomonic or specific neuroradiologic findings. Nevertheless, some features were typical and could help distinguish ES from other disorders. Spinal cord lesions were commonly multiple and discontinuous, usually not expansile, and centrally or ventrally positioned in the cord. Unlike the imaging usual pattern of dural arteriovenous fistula, which can also cause both upper and lower motor neuron problems, the cord lesions in ES are not consistently located in the most caudal portion of the conus. Dural arteriovenous fistula lesions, in contradistinction to ES, are usually continuous, extending rostral from the lowermost portion of the conus, involve the most of the thickness of the cord, and are commonly associated with swelling. Nerve root enhancement was sometimes diffuse and sometimes limited to ventral or dorsal roots. It was always smooth and continuous and never nodular or plaque like as can be seen with neoplastic nerve root lesions.^[@R10]^ Nerve root enhancement often occurred contemporaneously with spinal cord involvement, although either nerve root enhancement or spinal cord parenchymal signal abnormality could predominate; in some cases, root enhancement occurred at a later point of the illness as cord lesions were resolving. Finally, plaque or subpial cord enhancement, typical of granulomatous conditions,^[@R11]^ did not occur in patients with ES.

CSF examination demonstrated lymphocytic pleocytosis in 15 patients (50%), and in 3 of those (20%), neutrophils exceeded 5%.

Although HSV infection is widely believed to be responsible for a majority of cases, almost half of the cases (13/30) were never investigated for the presence of a viral infection even though lumbar puncture was performed, indicative of the low level of diagnostic suspicion for an infectious etiology for this condition. Furthermore, when PCR was performed, only 2 of the 30 (7%) were positive in the CSF and 1 from a genital swab. Despite CSF viral detection being considered the diagnostic gold standard, its diagnostic accuracy is imperfect in real-life settings,^[@R9],[@R12]^ with a negative predictive value of 82% and a positive predictive value of 54% in one study.^[@R9]^ Therefore, a negative result cannot absolutely exclude the presence of infection. Furthermore, rapid viral clearance from the CSF has been shown for HSV and VZV infections.^[@R13]^ The highest yield of viral detection by PCR occurred in samples obtained 3--14 days after symptom onset.^[@R9]^ In our cohort, samples were acquired outside this interval in 14 of the 18 cases (78%); the only 2 positive CSF PCR samples were obtained at days 11 and 37. Of the 3 patients who experienced an HSV infection immediately preceding ES, only 1 (33%) was tested within 14 days and 1 at day 15; none were positive for HSV infection in the CSF and 1 tested positive only from a genital swab.

Reported experience with CSF PCR in patients with ES is mostly limited to case reports and sometimes other viral detection methods, such as serology or culture, have been used.^[@R5]^ Antibody studies may be particularly useful when CSF is obtained late (e.g., \>14 days) in the course of the disease. Demonstration of intrathecal production of HSV- or VZV-specific immunoglobulin G (IgG) antibodies can be diagnostic.^[@R14],[@R15]^ Reliance on an antibody index comparing virus-specific IgG levels in CSF and serum with correction for blood-brain barrier leak using either the CSF/serum albumin ratio or the ratio of CSF/serum antibody titers of a nonpathogenic virus ensures that serum HSV or VZV antibodies have not reached the CSF by means of a sink mechanism. Although rarely demonstrated, the presence of virus-specific immunoglobulin M (IgM) in the CSF is strongly indicative of acute or active chronic CNS infection as these antibodies do not tend to cross the blood-brain barrier.

The 2 patients with a positive CSF PCR were positive for VZV. VZV may be considered an etiologic agent of ES,^[@R1]^ but is also recognized to be a cause of myelitis and/or myeloradiculitis occurring elsewhere in the spinal cord. The 2 patients with herpes zoster detection experienced more widespread involvement of the spinal cord than did other Elsberg cases. The first patient, who was immunocompetent, had a few discrete lesions higher in the cord and also had encephalitic manifestations; the second patient, who was HIV positive and immunocompromised, had a longitudinally extensive lesion spanning up to 9 vertebral segments of the thoracic spine and had evidence of meningeal irritation and necrotic cord damage. Ascending necrotic myelitis has been described in the setting of HSV2.^[@R16]^ Although the patients with VZV meet the criteria for ES, encephalitic symptoms as well as long thoracic and cervical cord MRI lesions and meningeal irritation may be considered red flags, and caution in the diagnostic process should be maintained before providing a final diagnosis.

HSV and VZV are treatable when acyclovir is initiated early, but the potential benefits of treatments with antiviral drugs have not been documented. In our cohort, none of the 5 patients with follow-up who received acyclovir experienced a fatal outcome. Yet, one patient treated with both acyclovir and corticosteroids had no clinical recovery as did one patient who received corticosteroid treatment alone and another who received neither ([table 4](#T4){ref-type="table"}). Therefore, superiority of acyclovir treatment cannot be proven. Nonetheless, acyclovir treatment was started only in 6 patients, whereas high-dose corticosteroids were administered as primary treatment in 15 patients, illustrating the low index of suspicion for this condition and the tendency to treat as an idiopathic inflammatory condition.

The study is limited by its retrospective nature. Because of the referral pattern of patients to our institution, patients were evaluated initially at outside institutions and as this study was retrospective, investigations were not standardized. Potentially, we did not capture all cases by our electronic search strategy. The proportion of laboratory-supported definite cases and of patients with proven HSV infection was low. This might reflect low rates of awareness of this syndrome and consequent low proportion of cases with acute and convalescent serology results. Limitations of sensitivity of viral isolation methods particularly when samples are obtained late in the course may be an additional contributor. Perhaps, next-generation sequencing may enhance diagnostic sensitivity as already shown with other infections.^[@R17]^

We recognize that the scientific literature is moving away from eponymous definitions. Our intent was not to entrench an eponymous definition, but to formalize diagnostic criteria that are flexible to aid in the identification of patients with combinations of radiculitis and caudal myelitis who have potentially treatable viral infections after considering clinical and radiologic clues that identify other potential etiologies for this syndrome. Improved testing and virus identification methodologies may establish the role of antiviral treatment.

ES is a definable condition that may be responsible for approximately 5%--15% of patients with CES and myelitis based on our review of cases seen at the Mayo Clinic. It is usually self-limited but commonly leaves some degree of permanent neurologic deficit and in one instance led to a fatal outcome. Although radiologic findings are not specific, they can help to rule out competing diagnoses, such as dural arteriovenous fistula, sarcoidosis, and other conditions. When both enhancement of cauda equina and signal abnormality of the distal spinal cord occur acutely, Elsberg may be a common cause of the syndrome. The diagnostic criteria that we formulated may bring attention to this condition and permit a more precise diagnosis when integrated with tests to exclude other mimics. Detection of viral infection is useful, but sensitivity appears to be low. Treatment with acyclovir is appropriate even in the absence of demonstration of viral infection given the favorable risk-benefit profile of this drug.
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